Anavex Life Sciences Corp (AVXL)

[sokol]

A few articles discuss the effects of SR1 agonists on sleep. [One article published in the journal Sleep Science and Practice ](https://sleep.biomedcentral.com/articles/10.1186/s41606-018-0025-z)[1](https://sleep.biomedcentral.com/articles/10.1186/s41606-018-0025-z) suggests that medications that target the sleep-associated circadian neuroendocrine system, such as SR1 agonists, can be used to treat insomnia. [Another article published in the journal Neuroscience Bulletin ](https://sleep.biomedcentral.com/articles/10.1186/s41606-018-0025-z)[2](https://link.springer.com/article/10.1007/s43440-021-00339-8) suggests that serotonergic signaling, which is modulated by SR1 agonists, plays a role in sleep and memory. However, I could not find any direct evidence that SR1 agonists improve sleep.

I do see where Anavex reported this about sleep in connection with the PDD study:  "Notably, blarcamesine did not impair sleep and had a positive effect on rapid eye movement (REM) sleep behavior disorder."  However, no details were provided.  See Blarcamesine Deemed Safe, Effective in Phase 2 Extension Study of Parkinson Disease Dementia.  https://www.neurologylive.com/view/blarcamesine-deemed-safe-effective-phase-2-extension-study-parkinson-disease-dementia

As to anxiety, this was reported about fear and anxiety in connection with the Rett clinical trial:  "Data from the phase 2 study was announced in 2021, with blarcamesine-treated patients showing significant increases in the expression of the SIGMAR1 mRNA biomarker, which correlated significantly with improvements in RSBQ (_P _= .035) and CGI-I (_P _= .029). Additionally, findings on the RSBQ demonstrated balanced improvements across all the instrument's subscales during the 7-week trial, including general mood, breathing, hand behavior, repetitive face movements, body rocking, night-time behavior, fear/anxiety, and walking/standing."  Phase 2/3 Study of Blarcamesine in Pediatrics With Rett Syndrome Completes Enrollment, Jun 8, 2023
By [Marco Meglio](https://www.neurologylive.com/authors/marco-meglio).  https://www.neurologylive.com/view/phase-2-3-study-blarcamesine-pediatrics-with-rett-syndrome-completes-enrollment.  Again, no details were provided.

What information- data will we receive from Anavex in connection with the latest on Rett and AD studies, including possibly open label data? Anything meaningful regarding sleep-anxiety, among other things?